ALLMedicine™ Mastocytosis Center
Research & Reviews 880 results
https://clinicaltrials.gov/ct2/show/NCT00044122
Feb 3rd, 2023 - This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number and survival in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving thera...
https://doi.org/10.1097/RLU.0000000000004564
Clinical Nuclear Medicine; García Vicente AM, Noriega Álvarez E et. al.
Feb 3rd, 2023 - Nocardia infection (nocardiosis) is usually acquired by inhalation; so pulmonary nocardiosis is the most common clinical presentation. Extrapulmonary localization occurs through hematogenous dissemination or contiguous spread. Nocardia can involve...
https://doi.org/10.1097/ACI.0000000000000869
Current Opinion in Allergy and Clinical Immunology; Tiano R, Krase IZ et. al.
Feb 3rd, 2023 - Paediatric mastocytosis is a rare clonal disorder characterized by the overproduction and organ infiltration of mast cells. Symptoms are due to mast cell mediator release. Cutaneous mastocytosis is the most common presentation in children with sys...
https://clinicaltrials.gov/ct2/show/NCT03770273
Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875486
BMC Cancer; Tiryaki TO, Özkan SG et. al.
Jan 25th, 2023 - Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wi...
Guidelines 3 results
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.
May 20th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...
https://doi.org/10.1111/j.1365-2222.2011.03788.x
Clinical and Experimental Allergy : Journal of the Britis... Krishna MT, Ewan PW et. al.
Aug 19th, 2011 - This guidance for the management of patients with hymenoptera venom allergy has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...
Drugs 263 results see all →
Clinicaltrials.gov 70 results
https://clinicaltrials.gov/ct2/show/NCT00044122
Feb 3rd, 2023 - This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number and survival in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving thera...
https://clinicaltrials.gov/ct2/show/NCT03770273
Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...
https://clinicaltrials.gov/ct2/show/NCT04910685
Jan 19th, 2023 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
https://clinicaltrials.gov/ct2/show/NCT02561988
Jan 13th, 2023 - This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult...
https://clinicaltrials.gov/ct2/show/NCT05186753
Jan 11th, 2023 - This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of CGT9486 plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdv...
News 129 results
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD
Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.
https://www.mdedge.com/dermatology/article/260439/contact-dermatitis/cutaneous-manifestations-hereditary-alpha-tryptasemia
Allison Kranyak, MD, Marshall Shuler, MD et. al.
Jan 3rd, 2023 - Hereditary alpha tryptasemia (HaT), an autosomal-dominant disorder of tryptase overproduction, was first described in 2014 by Lyons et al. 1 It has been associated with multiple dermatologic, allergic, gastrointestinal (GI) tract, neuropsychiatric,.
https://www.mdedge.com/familymedicine/article/260254/dermatology/incidental-skin-finding
MDedge Family Medicine;
Dec 19th, 2022 - This patient was given a diagnosis of cutaneous mastocytosis. The condition was previously known as urticaria pigmentosa, but in 2016 the World Health Organization reclassified the disease to better suit its pathophysiology as a myeloid cell disor.
https://www.mdedge.com/dermatology/article/259129/pediatrics/itchy-red-brown-spots-child
Deniz Demircioǧlu Duman, MD, Emel Öztürk Durmaz, MD
Nov 1st, 2022 - The Diagnosis: Maculopapular Cutaneous Mastocytosis (Urticaria Pigmentosa) A stroke test revealed urtication at the exact traumatized site (Figure). A skin biopsy performed 2 years prior by another physician in the same hospital had revealed mast.
https://www.medpagetoday.com/hematologyoncology/othercancers/100416
Aug 26th, 2022 - More evidence that first responders and clean-up crews at the site of the World Trade Center continue to have a heightened risk for multiple myeloma and the precursor condition monoclonal gammopathy of uncertain significance. (Sylvester Cancer Cen...